公开(公告)号：US20240216387A1

公开(公告)日：2024-07-04

申请号：US18557729

申请日：2022-01-05

Applicant: ANIMUSCURE INC.

Inventor： Sang-Jin LEE ,  Hyun-Kyung SO ,  Hye Yoyng LEE

IPC: A61K31/542 ,  A61K31/5415 ,  A61P21/00

CPC classification number: A61K31/542 ,  A61K31/5415 ,  A61P21/00

Abstract: The present invention relates to a composition for the purpose of preventing, alleviating, or treating a muscular disease, comprising an oxicam-based compound, wherein the composition strengthens muscles and increases muscle mass through the effects of promoting differentiation of myoblasts and increasing muscle fibers, and can, thereby, have a treatment effect for various muscular diseases and have muscle strengthening or motor performance increasing effects.

公开(公告)号：US20240261301A1

公开(公告)日：2024-08-08

申请号：US18562564

申请日：2021-10-25

Applicant: ANIMUSCURE INC.

Inventor： Sang-Jin LEE ,  Chang-Lim YOU ,  Ju-Hyeon BAE

IPC: A61K31/575 ,  A61P3/10 ,  A61P21/00

CPC classification number: A61K31/575 ,  A61P3/10 ,  A61P21/00

Abstract: The present invention relates to a composition comprising an inotodiol compound for prevention, alleviation, or treatment of muscular diseases. The composition increases skeletal muscle mass and promotes the regeneration of muscle fibers through self-renewal acceleration of muscle stem cells and differentiation promotion of myoblasts, and reinforces muscular strength by inducing the activation of mitochondrial functions, whereby the composition has prophylactic and therapeutic effects on various muscular diseases and an effect of increasing motor ability by reinforcing muscular strength.

公开(公告)号：US20240016891A1

公开(公告)日：2024-01-18

申请号：US18250629

申请日：2021-10-12

Applicant: ANIMUSCURE INC.

Inventor： Jong Sun KANG ,  Su Bin AN ,  Ju Hyeon BAE ,  Hye Been KIM

IPC: A61K38/17

CPC classification number: A61K38/177

Abstract: The present invention relates to a use of a cell adhesion molecule-related/down-regulated by oncogene (Cdo) protein or a gene encoding the same for preventing or treating neuromuscular diseases caused by damage to motor neurons, particularly muscle stem cells and neuromuscular junctions, due to aging, oxidative stress, and the like; and a method for screening for candidates for activating the expression of Cdo. When Cdo is deleted in motor neurons or neuromuscular junctions, aggravation of damage to degenerative motor neurons due to aging, and DNA damage caused by oxidative stress and inflammation are caused, which may cause neuromuscular diseases. Thus, the diseases can be treated through overexpression and activity of the Cdo protein and the gene encoding the same.

公开(公告)号：US20230372454A1

公开(公告)日：2023-11-23

申请号：US18248648

申请日：2021-10-12

Applicant: ANIMUSCURE INC.

Inventor： Jong Sun KANG ,  Hye Been KIM ,  Su Bin AN

IPC: A61K38/45 ,  A61P21/00 ,  G01N33/50

CPC classification number: A61K38/45 ,  C12Y201/01 ,  A61P21/00 ,  G01N33/5058 ,  G01N2333/91011

Abstract: The present invention relates to a use for, by using the protein arginine methyltransferase 1 (PRMT1) protein or a gene encoding the same, preventing or treating a neuromuscular disease induced by motor neurons, particularly, damage to motor neurons caused by oxidative stress in the neuromuscular junction; and a method for screening a candidate material for activating the expression of PRMT1. PRMT1 deficiency in the motor nerve or neuromuscular junction induces aggravated degenerative motor nerve damage caused by aging, and DNA damage caused by oxidative stress and inflammation, thereby enabling the induction of neuromuscular disease, and thus the disease may be treated through the overexpression and activity of the PRMT1 protein and a gene encoding the same.